FX.co ★ FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks

Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with the landmark FDA approval of its innovative drug, MIPLYFFA, for the treatment of Niemann-Pick disease type C. This regulatory milestone not only offers new hope for patients afflicted with this ultra-rare and progressive neurodegenerative disorder but has also driven Zevra's shares to a new 52-week high.

In addition to ZVRA, several other stocks highlighted on our site also reached new 52-week highs yesterday.

*Note: Last Closing Price refers to the stock's price at the close of trading on September 20, 2024.

**Related Reading**

"EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?"